{"url_path":"/sec/pvct/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/315545/0001493152-26-022950-index.html","accession_number":"0001493152-26-022950","cik":"0000315545","ticker":"PVCT","issuer_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/315545/0001493152-26-022950-index.html","primary_entity_key":"0000315545","primary_entity_name":"PROVECTUS BIOPHARMACEUTICALS, INC."},"word_count":142,"has_tables":true,"body_markdown":"**ITEM\n2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.**\n\n \n\n*2025 Financing*\n\n* *\n\nDuring the three months ended March 31, 2026, the\nCompany received 2025 Notes proceeds in the aggregate amount of $335,000, of which $110,000 was from a non-related party and $225,000\nwas from an officer and director of the Company.\n\n \n\n*Preferred\nConvertible Stock*\n\n \n\nDuring\nthe three months ended March 31, 2026, the Company issued 171,735 shares of restricted Series D-1 Convertible Preferred Stock upon the\nconversion of $455,000 of principal and $36,501 accrued interest, outstanding on the Company’s convertible notes.\n\n \n\nThe\nCompany believes that such transactions were exempt from the registration requirements of the Securities Act of 1933, as amended, (the\n“Securities Act”), in reliance on Section 4(a)(2) of the Securities Act (or Rule 506(b) of Regulation D promulgated thereunder)\nas transactions by an issuer not involving a public offering."}